Annovis Bio Inc. (NYSE: ANVS), a late-stage clinical drug platform company focused on neurodegenerative diseases, announced it will present new data on its lead drug candidate buntanetap at the 2025 Annual Meeting of the Parkinson Study Group, taking place Dec. 4–6 in San Diego. The presentation will expand on recent Phase 3 Parkinson's biomarker results, which indicate that patients with amyloid co-pathology experience more severe cognitive decline that is reversed by buntanetap. Additionally, the drug reduces tau biomarkers linked to disease progression.
Annovis will also debut a cross-study comparison of all completed trials, offering the most comprehensive view to date of cognitive outcomes across indications. This analysis underscores that patients with amyloid pathology achieve the greatest cognitive benefit, supporting the company's strategic path forward. The findings are significant because they suggest buntanetap may be effective in treating both Alzheimer's disease and Parkinson's disease, particularly in patients with overlapping pathologies.
The presentation comes as the company continues to advance its clinical programs. Buntanetap is designed to inhibit the formation of toxic proteins that contribute to neurodegeneration. The new data could provide insights into patient subgroups that respond best to treatment, potentially guiding future trial designs and regulatory strategies.
For more information, the full press release is available at https://ibn.fm/xiBPL. Annovis Bio is headquartered in Malvern, Pennsylvania, and is dedicated to addressing neurodegeneration in diseases such as Alzheimer's and Parkinson's. The company is committed to developing innovative therapies that improve patient outcomes and quality of life.
This announcement is important because it provides evidence that buntanetap may address cognitive decline in a subset of Parkinson's patients who have amyloid co-pathology, a group that often experiences more rapid deterioration. The cross-study comparison could also help clarify the drug's overall efficacy profile across different neurodegenerative conditions. Investors and researchers will be watching closely as Annovis presents these data, which could influence the company's regulatory and development milestones.
